Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — Q1 FY2026 Earnings Presentation
15 slides from Zim Laboratories's earnings presentation, Aug 7, 2025
Slide 1: Regulation 30 filing cover letter to BSE and NSE
Ref No.: ZLL/CS/BM/BSE-NSE Date : 07.08.2025 BSE Limited, National Stock Exchange of India Limited Market Operations Dept. Listing Compliance Department P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai – 400 051 Company Code- 541400 (Symbol - ZIMLA
Slide 2: Zim Laboratories Limited Earnings Presentation Q1FY26
ZIM LABORATORIES LIMITED E A R N I N G S P R E S E N TAT I O N Q1FY26 www.zimlab.in
Slide 3: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 4: Content
CONTENT 01 Q1FY26 HIGHLIGHTS 02 FINANCIAL PERFORMANCE – Q1FY26 03 BUSINESS MIX 04 R&D & INNOVATION 05 SHAREHOLDING 3
Slide 5: Q1FY26 Highlights
Q1FY26 HIGHLIGHTS Financial Highlights Business Highlights Total Operating Income at ₹718 Mn, We received 2 MA’s for Dutasteride down 12.3% YoY from ₹818 Mn in Tamsulosin & Rizatriptan Benzoate Oral Q1FY25 Films through our subsidiary in Australia 1 NIP filing done in EU; 4 NIP and 10 EBITDA is at ₹
Slide 6: Financial Performance – Q1FY26
FINANCIAL PERFORMANCE – Q1FY26 Total Operating Income EBITDA & EBITDA margin Profit After Tax (PAT) & PAT margin 11 % 7.9% 1.1 % -2.6% 9 818 Q1FY25 Q1FY26 90 718 57 -19 Q1FY25 Q1FY26 Q1FY25 Q1FY26 Q1FY25 Q1FY26 Q1FY25 Q1FY26 Q1FY25 Q1FY26 o Total Operating Income stood at ₹ 718 Mn primarily due to i
Slide 7: Business Mix
BUSINESS MIX Pharma Revenue (₹ Mn) & Contribution to Total Nutra Revenue (₹ Mn) & Contribution to Total Operating Income (%) Operating Income (%) 33% 82% 29% 77% 78% 71% 67% 23% 22% 18% 891 266 268 739 224 654 196 552 560 157 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 o Q1
Slide 8: Revenue Mix
REVENUE MIX 32, 4% 16, 2% 158, 4% 100, 14% 130, 3% 646, 18% 77, 9% 536, 14% Q1FY25 Q1FY26 FY24 FY25 2,870, 602, 84% 3,125, 709, 87% 78% 83% Numbers in ₹Mn Export India Deemed Export o Q1FY26: Revenue from exports decreased 15.2% YoY to ₹602 Mn, compared to ₹709 Mn in Q1FY25 o India Business grew 30.
Slide 9: Innovative Product Contribution
INNOVATIVE PRODUCT CONTRIBUTION (NIP + OTF) Revenue (₹ Mn) & Contribution to Operating Income (%) 21.8% 17.8% 14.0% 13.5% 12.7% 9.5% 178 8.5% 164 147 135 6.3% 109 112 82 46 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 License fees of ₹45 Mn in Q1FY26 vs ₹4 Mn in Q1FY25 o Q1FY26: NIP + OTF
Slide 10: Advancing Innovation: NIP Product Pipeline (EU/UK)
ADVANCING INNOVATION : NIP PRODUCT PIPELINE (EU/UK) Formulation Regulatory Regulatory Commercial Product Therapy Area Market Review Validation BE Studies Development Filing Approvals Supplies Product 1 Urology Product 2 Gastrointestinal Product 3 Anti – Coagulant Di-Methyl Fumarate CNS Product 5 Uro
Slide 11: Advancing Innovation: OTF Product Pipeline (EU/UK)
ADVANCING INNOVATION : OTF PRODUCT PIPELINE (EU/UK) Formulation Regulatory Regulatory Commercial Product Therapy Area Market Review Validation BE Studies Development Filing Approvals Supplies Rizatriptan CNS Sildenafil Erectile Dysfunction Product 3 CNS Product 4 Erectile Dysfunction Buprenorphine O
Slide 12: R&D Driving Product Innovation
R&D DRIVING PRODUCT INNOVATION R&D Expense Mix % of Total R&D Investment and Total R&D Investment as % of Total Operating Income 90 2 76 Capital Expenses on BE study, 24% registrations etc 43% 11% R&D Team Post- Size PhDs Graduates 12% 9.8% 1% Capital Expenses on Infrastructure & Equipment 8 4 ₹79 M
Slide 13: Income Statement
INCOME STATEMENT Particulars (₹ Mn) Q1FY26 Q1FY25 YoY% FY25 FY24 YoY% Total Operating Income 718 818 (12.3%) 3,790 3,674 3.2% Other Income 15 10 50% 58 52 13% Total Income 733 828 (11.6%) 3,848 3,725 3.3% EBITDA 57 90 (36.7%) 495 465 6.4% EBITDA % 7.9% 11% (310bps) 13.1% 12.7% 40bps Finance Cost 33
Slide 14: Shareholding
SHAREHOLDING Ownership % (June 2025) Traded Volume (In K) BSE+NSE 5% 26,593 33% 18,435 42% 14,093 14,104 11,313 5,734 12% 8% Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Promoter HNI Body Corporates Other Public Shareholding • Number of Shareholders in Q1FY26 accounted to 16.64K NRI & Foreign Individua
Slide 15: Investor Relations Company Contact
Investor Relations Company Contact Mr. Zain Daud Ms. Sheetal Khanduja Address Zim Laboratories Limited Go India Advisors Sadoday Gyan (Ground Floor), Opposite NADT, Nelson Square, zain.daud@zimlab.in sheetal@GoIndiaAdvisors.com Nagpur, Maharashtra 440013 M:+91 9022434631 M:+91 97693 64166 www.zimlab